Supriya Lifescience, a pharmaceutical company, has received a tax demand notice of ₹603.80 crore from the Tax Department. The company has not provided specific details about the nature of the tax assessment or the period it covers. This substantial demand could potentially impact the company's finances and operations. Investors are awaiting further information and the company's response to this development.
Supriya Lifescience announced robust growth plans during a recent conference call. The company's formulation facility is expected to generate ₹450-500 crore in revenue. They maintained a 20% annual revenue growth guidance with EBITDA margins of 33-35%. A mid-term goal of ₹1,000 crore revenue by FY2027 was set. The company anticipates stronger volume growth over the next two years, driven by full capacity utilization of Module E by FY27 and launch of new products with significant global volume potential.
Supriya Lifescience Ltd. has released its Q4 financial results, showing significant year-over-year growth. Revenue increased by 16.46% to ₹1,840.00 million, EBITDA rose by 21.80% to ₹676.00 million, and net profit surged by 36.59% to ₹504.00 million. The company's EBITDA margin expanded to 36.72% from 35.09% in the previous year. Quarter-on-quarter growth was also notable, with net profit increasing by 7.69%. The board has recommended a dividend of ₹1.00 per equity share.